DANIELA GANESCU: Open Payments
NPI 1669572228 · TRENTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$956 in 53 payments from 9 companies in 2025. Trend: 2023 $483 · 2024 $902 · 2025 $956
Food & beverage: $956
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $231 |
| Alkermes, Inc. | 9 | $161 |
| Teva Pharmaceuticals USA, Inc. | 10 | $156 |
| E.R. Squibb & Sons, L.L.C. | 7 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Janssen Pharmaceuticals, Inc | 3 | $49 |
| ABBVIE INC. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: INGREZZA, UZEDY, ARISTADA, COBENFY, CAPLYTA, ABILIFY MAINTENA, INVEGA SUSTENNA, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
